Porton Pharma Solutions Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Porton Pharma Solutions şirketinin toplam hissedar öz sermayesi CN¥5.6B ve toplam borcu CN¥1.4B olup, bu da borç-öz sermaye oranını 24.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥8.9B ve CN¥3.4B dir.

Anahtar bilgiler

24.7%

Borç/özkaynak oranı

CN¥1.37b

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥1.40b
Eşitlik	CN¥5.55b
Toplam yükümlülükler	CN¥3.37b
Toplam varlıklar	CN¥8.92b

Son finansal sağlık güncellemeleri

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26

Recent updates

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Nov 14

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Sep 30

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300363 'nin kısa vadeli varlıkları ( CN¥3.2B ) kısa vadeli yükümlülüklerini ( CN¥1.5B ) aşıyor.

Uzun Vadeli Yükümlülükler: 300363 şirketinin kısa vadeli varlıkları ( CN¥3.2B ) uzun vadeli yükümlülüklerini ( CN¥1.9B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300363 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 300363 şirketinin borç/öz sermaye oranı son 5 yılda 18.5% seviyesinden 24.7% seviyesine yükseldi.

Borç Kapsamı: 300363 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 300363 şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Bilanço

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/27 18:56
Gün Sonu Hisse Fiyatı	2024/12/27 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Porton Pharma Solutions Ltd. 10 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jin Zhang	China International Capital Corporation Limited
Feifei Xu	China Merchants Securities Co. Ltd.
Zhu Chen	Citic Securities Co., Ltd.

Porton Pharma Solutions Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Recent updates

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Price target increased by 34% to CN¥20.00

Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023)

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

New minor risk - Share price stability

Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023)

Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Price target decreased by 29% to CN¥20.30

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023)

Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024

Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Investor sentiment deteriorates as stock falls 15%

Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Price target decreased by 11% to CN¥33.00

Consensus EPS estimates increase by 12%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 10%

New major risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022)

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 19%

Price target decreased by 9.8% to CN¥37.00

Consensus EPS estimates fall by 43%, revenue upgraded

Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022)

Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023

Upcoming dividend of CN¥1.11 per share at 3.2% yield

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.7% to CN¥70.63

Investor sentiment improved over the past week

High number of new directors

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 21%

Price target decreased to CN¥104

Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021)

Porton Pharma Solutions Ltd. (SZSE:300363) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

High number of new directors

High number of new and inexperienced directors

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Porton Pharma Solutions Ltd. Announces Final Dividend for 2021, Payable on 28 April 2022

Porton Pharma Solutions Ltd. Approves Cash Dividend for 2021

Consensus revenue estimates increase by 52%

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 18, 2022

Porton Pharma Solutions Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020)

Porton Pharma Solutions Ltd. (SZSE:300363) agreed to acquire 70% stake in Hubei Yuyang Pharmaceutical Co., Ltd. from a group of shareholders for approximately CNY 170 million.

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020)

Porton Pharma Solutions Ltd. Announces on 15 March 2021 the Profit Distribution Proposal for 2020

Porton Pharma Solutions Ltd., Annual General Meeting, Apr 06, 2021

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019)

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019)

Revenue beats expectations

New 90-day high: CN¥46.67

Zhangjiagang Zhuoyuan Investment Partnership (Limited Partnership) completed the acquisition of 5.24% stake in Porton Pharma Solutions Ltd. (SZSE:300363) from Ju Nianfeng, Tao Rong, and Zhang Hebing.

Porton Pharma Solutions Ltd. to Report Fiscal Year 2020 Results on Mar 13, 2021

New 90-day high: CN¥42.13